Nicholas Turner
Royal Marsden NHS Foundation Trust · Royal Marsden Hospital NHS- Institute of Cancer Research · Institute of Cancer Research, United Kingdom
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nicholas Turner as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:13 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05058183 · Safe De-escalation of Chemotherapy for Stage 1 Breast CancerRoyal Marsden NHS Foundation Trust · recruiting · Breast Cancer · principal investigator
- Ph2NCT04985266 · A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRoyal Marsden NHS Foundation Trust · recruiting · ER+ Breast Cancer, HER2-negative Breast Cancer · principal investigator
- Ph2NCT02423603 · PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast CancerQueen Mary University of London · completed · Metastatic Breast Cancer · principal investigator
- Ph1NCT02389842 · PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibRoyal Marsden NHS Foundation Trust · completed · Advanced Solid Tumours, Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:13 UTC. The ranking covers the 200 most relevant of 121 PubMed records, and a shared surname and initials can bring in a namesake. All 121 on PubMed
- 1,471 citationsRCR 45.8
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.N Engl J Med · 20151,289 citationsRCR 36.8
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med · 20181,016 citationsRCR 33.5
- Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med · 2023702 citationsRCR 63.3
- Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.J Clin Oncol · 2016594 citationsRCR 17.6
- The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.Cancer Discov · 2018534 citationsRCR 16.0
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.Lancet Oncol · 2021432 citationsRCR 21.2
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.J Clin Oncol · 2019371 citationsRCR 12.2
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.Nat Commun · 2018349 citationsRCR 10.4
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.J Clin Oncol · 2020341 citationsRCR 14.1